‘Combination of medications prolongs life expectancy alvleesklierkankerpatiënten’
The life expectancy of people suffering from pancreatic cancer, one of the most deadly types of the disease, may be extended thanks to a combination of two drugs.
As patients after surgery, the cancer drugs gemcitabine and capecitabine, take, lives almost 29 percent of them for at least five years longer. This is evident from a testonderzoek, published in The Lancet, which was held by the university of Liverpool among more than 700 patients.
After their surgery, the treatment using both drugs compared with treatment with only gemcitabine was administered.
28.8 percent, percent of the patients who are both medications used, then lived at least another five years. This is true for 16.3 percent of the alvleesklierkankerpatiënten that only gemcitabine used.
According to Pancreatic Cancer UK, the foundation for alvleesklierpatiënten in Britain, this combination of medications are available for all patients for the treatment are eligible. This would mean that each year, some 100 patients have a life expectancy of at least five years.
Currently he lives only five percent of the patients five years or more and one per cent longer than ten years. Since the seventies, the survival rate of the disease is hardly improved.
In the Netherlands every year approximately 2,000 people are diagnosed with the disease.